Official Title
Expanded Access Use of OFEV (Nintedanib) in Non-IPF Interstitial Lung Disease
Brief Summary

This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.

Approved for marketing
Individual Patients
Lung Diseases, Interstitial

Drug: OFEV

twice daily

Eligibility Criteria

Inclusion Criteria:


Exclusion Criteria:

- Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary
Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation
in this Expanded Access Program (EAP).

Eligibility Gender
Eligibility Age
Minimum: N/A ~ Maximum: N/A
United States

Banner University Medical Center Tucson
Tucson, Arizona, United States

The Lung Research Center, LLC
Chesterfield, Missouri, United States

Glacier View Research Institute
Kalispell, Montana, United States

University of Rochester Medical Center
Rochester, New York, United States

Centra Medical Group
Bedford, Virginia, United States

Inova Fairfax Medical Campus
Falls Church, Virginia, United States

Boehringer Ingelheim
NCT Number
MeSH Terms
Lung Diseases
Lung Diseases, Interstitial